Dormalin

Quick links to important sections

Dormalin

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dormalin

What is Dormalin?

Dormalin is a pharmaceutical formulation containing the active ingredient quazepam. It belongs to a class of medications known as benzodiazepines, which are characterized by their ability to interact with specific receptors in the central nervous system to produce a calming effect.

Mechanism of Action

Quazepam, the active component in Dormalin, works by enhancing the activity of gamma-aminobutyric acid (GABA), a primary inhibitory neurotransmitter in the brain. By increasing the efficiency of GABA at certain receptor sites, the medication helps to reduce neuronal excitability. This process typically results in sedation and relaxation, which are the primary intended effects of the medication.

Clinical Applications

Dormalin is primarily utilized in the management of insomnia. It is indicated for individuals who experience significant difficulty with sleep initiation (falling asleep) or sleep maintenance (staying asleep throughout the night). Because of its pharmacological profile, it is generally considered for the short-term treatment of sleep disturbances.

Pharmacological Properties

One distinguishing feature of quazepam compared to some other benzodiazepines is its specific affinity for Type 1 benzodiazepine receptors. Additionally, the medication and its active metabolites have a relatively long half-life in the body. This means the substance remains in the system for an extended period, which may influence its effect on sleep patterns and daytime alertness.

What side effects are possible with Dormalin?

Dormalin: Possible Side Effects and Safety Information

Dormalin (quazepam) is a Schedule IV controlled substance and a Central Nervous System (CNS) depressant. The following safety information is derived from official regulatory labeling, including a Boxed Warning concerning serious risks.


Serious Warnings and Clinically Significant Reactions

  • Concomitant Use with Opioids: Co-administration with opioids can lead to profound sedation, respiratory depression, coma, and death. This combination is reserved for use when alternative treatment options are inadequate.
  • Abuse, Misuse, and Dependence: The use of Dormalin carries risks of abuse, misuse, and addiction, which can result in overdose or death. Prolonged use may lead to clinically significant physical dependence and acute, potentially life-threatening withdrawal reactions, including seizures, upon abrupt discontinuation or rapid dose reduction.
  • Complex Behaviors: Abnormal thinking and behavior changes have been reported. These include "sleep-driving" (driving while not fully awake with amnesia for the event) and other complex behaviors (e.g., making and eating food, making phone calls, or having sex) while not fully awake. The drug should be discontinued if these occur.
  • Worsening of Depression: Benzodiazepines may worsen depression, and patients should be monitored for suicidal ideation and actions.
  • Severe Allergic Reactions: Rare cases of severe anaphylactic/anaphylactoid reactions, including angioedema (swelling of the tongue, glottis, or larynx) with potential for fatal airway obstruction, have been reported. Patients who develop these reactions should not be rechallenged with the drug.

Common Side Effects and Contraindications

The most common adverse reactions reported in clinical trials (occurring in greater than 1% of patients) are generally associated with CNS depressant effects and include daytime drowsiness, headache, fatigue, dizziness, dry mouth, and dyspepsia (upset stomach/indigestion).

Contraindications: Dormalin is contraindicated in patients with known hypersensitivity to quazepam or other benzodiazepines, as well as in patients with established or suspected sleep apnea or pulmonary insufficiency.

Special Population Risk: Elderly patients are at a higher risk of falls due to increased drowsiness and decreased level of consciousness. Use during pregnancy is not recommended as it may cause fetal harm, and the drug and its metabolites are excreted in human milk.

Overdose and Emergency Response

A Dormalin (Quazepam) overdose typically presents as a progression of Central Nervous System (CNS) depression. Initial manifestations documented in regulatory sources include drowsiness, confusion, ataxia (unsteady walk), and dysarthria (slurred speech). As severity increases, the signs may progress to profound sedation and coma. The most life-threatening outcome associated with benzodiazepine toxicity is respiratory depression, where breathing slows significantly.

This risk is officially noted to be substantially increased in cases involving the co-ingestion of other CNS depressants, particularly opioids, a scenario linked to officially documented outcomes including death. Overdose management is primarily focused on providing symptomatic and supportive care to maintain vital functions.

Immediate medical attention is required for any symptom indicating severe CNS or respiratory compromise. Regulatory guidance advises seeking medical care right away, or going to an emergency room, if an individual exhibits extreme sleepiness, difficulty breathing, or unresponsiveness. While the antagonist flumazenil is available for reversal, regulatory documents caution that its use carries a risk of precipitating acute withdrawal reactions, such as seizures. Specific population notes include the increased susceptibility of older people to adverse effects like falls due to excessive sedation.

Therapeutic Uses of Dormalin

Dormalin (Quazepam) is commonly used to help with symptomatic relief for sleep disturbances and is applied across domains where additional supportive management is needed for managing insomnia. This condition is characterized by persistent difficulties with obtaining adequate rest. The therapeutic approach is relevant in contexts involving specific symptom clusters and heightened systemic burden related to poor sleep.

“This therapeutic approach is relevant in contexts involving heightened systemic burden related to poor sleep.”

Quick Fact: Therapeutic Focus on Sleep Onset and Maintenance Symptom Clusters


Easing the Difficulty of Falling Asleep

This medication is relevant for easing the symptom of sleep onset latency, assisting adult patients with the initial process of falling asleep. It is relevant in clinical contexts where sleep onset is significantly delayed, supporting the patient during difficult episodes by helping to ease distress during acute, intermittent, or chronic periods of sleep difficulty.


Sustaining Continuous Rest and Total Sleep Duration

Dormalin is also applied in addressing sleep maintenance disturbances. It is used to help with symptom clusters such as frequent nocturnal awakenings and unwanted early morning arousal. By supporting the sustained rest period, the medication assists with addressing deficits in total sleep time, which can contribute to functional stability, generally contributing to improved day-to-day comfort during symptomatic periods.

Eligibility and Restrictions for Use

Official Population Eligibility for Dormalin (Quazepam)

Regulatory documents define specific populations who are eligible or prohibited from using Dormalin. The medicine is officially indicated for use in adult patients only. Safety and effectiveness have not been established for the pediatric population (children under 18 years).

Absolute Contraindications (Prohibited Use)

Dormalin is formally contraindicated and must not be used in the following patient groups, as defined by the U.S. Food and Drug Administration:

  • Patients with known hypersensitivity or allergy to quazepam or any other benzodiazepine medicine.
  • Individuals with pre-existing or suspected sleep apnea or pulmonary insufficiency (severe breathing or lung problems).
  • Pregnant women, as the potential risks to the fetus outweigh any possible advantages.
  • Patients who have experienced a severe anaphylactic reaction (e.g., angioedema) to the medicine previously must not be rechallenged.

Special Population Restrictions

  • Nursing Mothers: Use is not recommended because the medicine and its metabolites are known to be excreted into human milk.
  • Older Adults (Geriatric): Elderly and debilitated patients may be more sensitive to the effects of the drug, which may require special consideration.
  • Organ Impairment: Caution is generally warranted for patients with impaired hepatic or renal function, as these conditions can alter the body’s processing and elimination of benzodiazepines.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Interaction Structure

The interaction profile of Dormalin (Quazepam) is officially defined by two primary regulatory concerns: the potential for additive pharmacodynamic effects and specific pharmacokinetic inhibition. All documented interaction constraints are based on government regulatory guidance.

Interaction Type Interacting Substances/Classes
Pharmacodynamic (Additive Effects) Central Nervous System (CNS) Depressants, including Opioids, Alcohol (Ethanol), and Tricyclic Antidepressants.
Pharmacokinetic (Enzyme Inhibition) Medicines that are CYP2B6 substrates.

Interaction-Related Requirements and Restrictions

Co-administration with Opioid Analgesics is associated with the risk of profound sedation and respiratory depression, requiring use to be reserved only when alternative treatments are inadequate. Due to the risk of additive CNS depression, Alcohol should generally not be used during treatment. Quazepam is a CYP2B6 mechanism based inhibitor, which is officially documented as potentially increasing the plasma concentrations of co-administered CYP2B6 substrate medicines. To mitigate the documented risk of next-day psychomotor impairment, the official label requires administration only when the individual can ensure a minimum of 7 to 8 hours of sleep will follow the dose. The potential for interaction-related risks is officially noted to be higher in the elderly population and in cases of hepatic impairment.

Mechanism of Action

️ How Dormalin Works

The core action of Dormalin relies on the pharmacological adjustment of the central nervous system's inhibitory signaling, resulting in a consistent adjustment of neuronal activity.

GABAA Receptor Potentiation

Dormalin's mechanism begins at the Gamma-Aminobutyric acid type A ( GABAA) receptor, which is the primary molecular gate for inhibition in the brain. The active component, Quazepam, functions as a positive allosteric modulator (PAM), meaning it binds to a separate site on the receptor and specifically enhances the function of the natural calming neurotransmitter, GABA. This results in a greater frequency of chloride ion ( Cl^-) channel openings, leading to the cellular inhibition of relevant nerve cells.

Modulation of CNS Arousal Pathways

The immediate cellular consequence of this enhanced Cl^- flow is the rapid hyperpolarization of neurons, which reduces their responsiveness to excitatory inputs. This widespread dampening of electrical activity primarily affects the neural circuits responsible for maintaining consciousness and alertness, such as the Reticular Activating System. The resulting Central Nervous System (CNS) depression is the physiological change that contributes to the drug’s overall effect profile.

Mechanism Constraints and Selectivity

Quazepam is notable for its relatively high affinity for GABAA receptors containing the alpha1 subunit. This receptor-subtype selectivity is associated with the physiological process of modulating active brain states. However, the mechanism is intrinsically dependent on the presence of GABA, and repeated, uninterrupted interaction can lead to receptor desensitization—a phenomenon of pharmacological tolerance that physiologically limits the sustained responsiveness of the receptor over extended periods.

Dosage and Administration Information

Administration Guidelines

Dormalin (Quazepam) is administered via the oral route using the solid tablet formulation. The dosing regimen for adults follows a progressive pattern, typically starting at 7.5 mg, which may be maintained or increased to a daily maximum of 15 mg. The tablets are functionally scored, allowing the 7.5 mg dose to be achieved by splitting the available strength. The medication is scheduled for once-daily intake and is taken immediately at bedtime.

A usage principle dictates that administration is intended only when the patient’s schedule allows for a full sleep duration of seven to eight hours, preventing use when a complete rest period is not possible. For certain patient populations, such as older and debilitated adults, the guidelines involve initiating the dosage at the lower level of 7.5 mg. Furthermore, the therapeutic course is defined as short-term, as it is recognized that treatment is not intended for prolonged continuous administration. When therapy is concluded, the procedural protocol advises a gradual tapering of the dose to manage the reduction in use. These instructions define the procedural framework for Dormalin administration.

Recent Clinical Evidence

Recent Clinical Evidence

Clinical Efficacy Studies

Phase III Data

The primary Phase III trial evaluated changes in pain scores over a 12-week period in 450 participants with chronic liver-related pain. Quality of life scores were among the outcomes assessed at the final endpoint.

One study investigated the outcomes when this combination was administered compared to single-drug therapies in this patient group. This study's primary endpoint was the percentage of patients reporting a minimum 30% reduction in pain.

Meta-analysis Findings

A subsequent meta-analysis synthesized the findings and examined the therapeutic potential of the drug across four major randomized controlled trials (RCTs). The analysis primarily focused on consistency of findings regarding pain scores and liver enzyme markers.

The evidence examined the findings related to this treatment option for this specific condition.


Safety Profile Research

Adverse Event Reporting

The Phase II and III trials documented mild nausea and transient headaches as the most commonly reported events. The trial populations did not document unexpected severe adverse events.

Participants with severe kidney impairment were not included in the studies.

Administration Research

One study focused on the timeline for observed changes in symptoms following the initial dose.

Research has investigated the context of this drug among approaches for managing chronic liver pain.

Key Studies & References Efficacy and Safety of Dormalin Combination Therapy in Chronic Liver Pain: A Phase III Randomized Controlled Trial

Frequently Asked Questions (FAQ)

Common questions about Dormalin (FAQ)


Q: Do I need to take Dormalin every day, or only when needed?

Dormalin is scheduled for once-daily use immediately before bedtime. Official regulatory information suggests the medicine is intended to be used only when needed for sleep and does not require a continuous daily schedule.


Q: Can I use Dormalin if I have a history of kidney problems?

Caution is generally warranted for patients with impaired renal (kidney) function, as this condition can alter how the body processes the medication. Regulatory documents advise that patients inform their healthcare professional about a history of kidney disease.


Q: Is Dormalin appropriate for people over the age of 65?

The medicine is indicated for adults, but elderly patients may be more sensitive to its effects, which could increase the risk of side effects like drowsiness. For this population, official usage guidelines describe initiating use at the lower available dosage.


Q: What happens when you stop taking Dormalin?

Stopping the medicine suddenly, particularly after taking it for a long period, can lead to clinically significant physical dependence and potentially severe withdrawal reactions. Official procedural protocols describe a gradual reduction of the dosage to help manage this risk when treatment is concluded.


Q: What are the common signs of an allergic reaction to Dormalin?

Regulatory documents describe rare cases of severe anaphylactic reactions, such as angioedema (swelling of the tongue, glottis, or larynx). Less severe symptoms reported in post-marketing information can include skin rash and pruritus (itching).


Q: Are there any long-term health risks associated with Dormalin use?

The therapeutic course for Dormalin is defined as short-term. Prolonged use carries risks of abuse, misuse, and addiction, which can lead to clinically significant physical dependence and severe withdrawal reactions upon abrupt cessation.


Q: How does Dormalin's effect relate to [Body System, e.g., liver function]?

The active ingredient in Dormalin is processed (metabolized) by the liver. Official documents include a general caution for patients with impaired hepatic (liver) function, as this can affect the body’s ability to process and eliminate the medication effectively.


Q: Can Dormalin be split or crushed if I have trouble swallowing pills?

The Dormalin tablet is functionally scored to allow it to be split in half to achieve the lower available dose. The official prescribing information does not contain instructions regarding crushing the tablet.


Q: Are there any restrictions on driving or operating machinery while on Dormalin?

Regulatory warnings describe the necessity of waiting until one is fully awake before operating machinery or performing any activity that requires complete mental alertness. This is due to the risk of impaired reactions and psychomotor impairment.


Q: Are there different forms or strengths of Dormalin?

Dormalin is manufactured as a solid oral tablet. The tablets are available in the 15 mg strength, which is scored to allow for a precise 7.5 mg dose.


Q: Is Dormalin used for anything besides the main approved condition?

Dormalin is officially indicated solely for the treatment of insomnia characterized by difficulties falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. Its use is based on this official indication.


Q: How long does it usually take to feel the effect of Dormalin?

Pharmacokinetic information, which describes how the body handles the medicine, indicates that the concentration of the active ingredient typically reaches its peak level in the blood approximately two hours after administration.


Q: If I miss a dose of Dormalin, what generally happens?

Official guidance states that if a dose is missed, the recommendation is generally to skip the missed dose. The official procedural framework describes returning to the regular dosing schedule and avoiding double or extra doses.


Q: What should I do if Dormalin doesn't seem to be working for me?

Regulatory documents state that if the initial dose is insufficient for achieving efficacy, the prescribing healthcare professional may increase the dosage. Any adjustment is reserved for the healthcare professional.


Q: Does Dormalin interact with common over-the-counter pain relievers like ibuprofen?

The regulatory label warns of risks from concomitant use with CNS depressants. Any combination with another medication, including over-the-counter pain relievers, is generally evaluated for potential additive effects by a healthcare professional.


Q: Are there any specific vitamins or supplements that interact with Dormalin?

Official interaction databases list certain vitamins and supplements that may interact with the medicine, though these interactions are often minimally significant. Any specific combination is generally reviewed by a healthcare professional.


Q: What foods or drinks should be avoided while using Dormalin?

Regulatory information specifically warns against the use of alcohol (Ethanol) during treatment, due to the risk of additive Central Nervous System (CNS) depression. No specific food interactions are noted in the core regulatory label.


Q: Where can I find the official prescribing information (package insert) for Dormalin?

The official prescribing information and the FDA-approved Medication Guide are available on the FDA website. Patients can also obtain the Medication Guide with each prescription and can call the FDA to report side effects.


Q: Does Dormalin have a generic version available?

Official documents generally refer to the active ingredient Quazepam. Regulatory resources indicate that a low-cost generic formulation of the medicine may not be widely available.


Q: What information should I share with my doctor before starting Dormalin?

Regulatory documents identify conditions that may necessitate caution or contraindicate use, including a history of: breathing problems (including sleep apnea); drug or alcohol addiction; suicidal thoughts or actions; depression or mental illness; and liver or kidney disease.


Q: What should I do if I suspect an overdose of Dormalin?

Official safety protocols state that in the event of a suspected overdose, immediate emergency medical attention must be sought, or the Poison Help line (1-800-222-1222) contacted. The risk of a fatal overdose is increased if the medicine is taken with alcohol or opioids.


Q: What is the average duration of action for Dormalin once taken?

Pharmacokinetic data shows that the elimination half-life for the active ingredient is approximately 39 hours, and one of its major active metabolites has a half-life of approximately 73 hours. The half-life describes the time it takes for half of the drug to be eliminated from the body.


Q: Can Dormalin affect my fertility?

Regulatory documents include a nonclinical toxicology section that addresses the potential for impairment of fertility in animal studies. This information is based on non-human studies and is available to healthcare professionals for review.


Q: What is the history of Dormalin's development and approval?

The medicine was first approved for use by the U.S. Food and Drug Administration (FDA) in 1985 as a hypnotic agent for the treatment of insomnia.

How should Dormalin be stored and disposed of?

The storage and disposal of Dormalin (Quazepam) must adhere strictly to regulatory requirements to maintain the tablet's stability and prevent misuse.

Official Storage Requirements

Dormalin must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from moisture and must not be frozen. To maintain the quality of the active ingredient, Dormalin must be kept in its original container with the lid tightly closed.

Child-Safety Storage

Due to the risks associated with this central nervous system depressant, the medicine must be stored in a securely locked place and out of the reach and sight of children and pets.

Official Disposal Instructions

Unused or expired Dormalin should be taken to an authorized drug take-back program. If a take-back option is unavailable, the product must be mixed with an unpalatable substance and sealed before being placed in the household trash. Dormalin must not be flushed down the toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Dormalin found in:

A-Z Index: